Individuals with insomnia and objective short sleep duration (ISSD) are at higher risk for incident cardiovascular disease (CVD) and cerebrovascular disease (CBVD), according to results of a study published in the Journal of the American Heart Association.
Emerging evidence suggests there is a bidirectional relationship between disturbed sleep and risk for CVD and CBVD.
….these findings underscore the clinical importance of objective sleep assessment in patients with insomnia which may lead to more personalized approaches to cardiovascular and cerebrovascular risk reductions.
Compared with individuals who had normal sleep and normal sleep duration, ISSD increased risk for both CVD (adjusted hazard ratio [aHR], 1.39; 95% CI, 1.11-1.74; P =.004) and CBVD (aHR, 1.77; 95% CI, 1.30-2.40; P =.001).
Similarly, ISSD remained associated with CVD (aHR range, 1.39-1.49) and CBVD (aHR range, 1.68-1.86) risk in step-by-step analyses with different covariates.
Individuals with insomnia and objective short sleep duration (ISSD) are at higher risk for incident cardiovascular disease (CVD) and cerebrovascular disease (CBVD), according to results of a study published in the Journal of the American Heart Association.
Emerging evidence suggests there is a bidirectional relationship between disturbed sleep and risk for CVD and CBVD.
Investigators in the United States analyzed data for this study from the UK Biobank. Individuals (N=8762) who had 1-week objective sleep data collected by accelerometer between 2013 and 2016 and self-reported whether they experienced symptoms of insomnia were evaluated for CVD and CBVD. Short sleep duration was defined as fewer than 7.3 hours per night.
The study population comprised 46.3% men;, mean age was 60.05 years;, mean body mass index was 26.75;, 29.5% of patients reported insomnia;, mean total sleep time was 7.22 hours;, 20.5% of patients were diagnosed with CVD;, and 12.1% of patients were diagnosed with CBVD.
….these findings underscore the clinical importance of objective sleep assessment in patients with insomnia which may lead to more personalized approaches to cardiovascular and cerebrovascular risk reductions.
Compared with individuals who had normal sleep and normal sleep duration, ISSD increased risk for both CVD (adjusted hazard ratio [aHR], 1.39; 95% CI, 1.11-1.74; P =.004) and CBVD (aHR, 1.77; 95% CI, 1.30-2.40; P =.001).
Similarly, ISSD remained associated with CVD (aHR range, 1.39-1.49) and CBVD (aHR range, 1.68-1.86) risk in step-by-step analyses with different covariates.
As many CBVD events occurred before the sleep assessment, a model containing an age-by-time interaction was conducted, and the relationship between ISSD and CBVD remained significant (aHR, 1.76; 95% CI, 1.29-2.39; P <.001).
The major limitation of this study was that the insomnia assessment comprised a single self-reported question.
The study investigators concluded, “…this study provides compelling evidence that ISSD significantly increases cardiovascular and cerebrovascular risk in the UK population….these findings underscore the clinical importance of objective sleep assessment in patients with insomnia which may lead to more personalized approaches to cardiovascular and cerebrovascular risk reductions.”
